Alan Paul Lombard, Ph.D.
Assistant Professor, Urologic Surgery and Biochemistry and Molecular Medicine
Specialties
Prostate Cancer
Urologic Oncology
Therapeutic Response and Resistance
Locations and Contact
Oak Park Research Center Building
Department of Biochemistry and Molecular Medicine
2700 Stockton Blvd.
Sacramento, CA 95817
Phone: 916-734-4417
Additional Numbers
Phone
Research/Academic Interests
Dr. Lombard's research centers on the study of prostate cancer and mechanisms underlying its progression and both response and resistance to therapy. His lab's current focus is on the integration of PARP inhibitor treatment strategies into clinical care and the design of novel combination therapies which will enhance PARP inhibitor efficacy. Specific interests include studies to understand treatment induced senescence and how we may target senescent cells within the tumor microenvironment using rationally selected senolytic drugs.
Division
Biological Chemistry
Urology
Undergraduate School
B.S., Biology and Bioinformatics, Rensselaer Polytechnic Institute, Troy NY 2010
Other School
Ph.D., Biochemistry, Molecular, Cellular, and Developmental Biology, UC Davis, Davis CA 2015
Fellowship
Urologic Surgery/Postdoctoral Studies, UC Davis, Sacramento CA 2015-2021
Minority Scholar Award, Society for Basic Urologic Research, 2022
Campos Faculty Scholar (8th Cohort), UC Davis Office of DEI, 2022
Eddie Mendez Scholar Award, Fred Hutchinson Cancer Research Center, 2021
NCI K01 - Mentored Research Scientist Development Award to Promote Diversity, 2021
Society for Basic Urologic Research (SBUR) Travel Award, 2016, 2018, 2020
To see a full list of Dr. Lombard's publications, please click here.
Ning S, Liu C, Lou W, Yang JC, Lombard AP, D'Abronzo LS, Batra N, Yu AM, Leslie AR, Sharifi M, Evans CP, Gao AC. Bioengineered BERA-Wnt5a siRNA Targeting Wnt5a/FZD2 Signaling Suppresses Advanced Prostate Cancer Tumor Growth and Enhances Enzalutamide Treatment. Mol Cancer Ther. 2022 Oct 7;21(10):1594-1607. doi:10.1158/1535-7163.MCT-22-0216. PMID:35930737.
Lombard AP, Armstrong CM, D'Abronzo LS, Ning S, Leslie AR, Sharifi M, Lou W, Evans CP, Dall'Era M, Chen HW, Chen X, Gao AC. Olaparib-Induced Senescence Is Bypassed through G2-M Checkpoint Override in Olaparib-Resistant Prostate Cancer. Mol Cancer Ther. 2022 Apr 1;21(4):677-685. doi:10.1158/1535-7163.MCT-21-0604. PMID:35086956.
Lombard AP, Lou W, Armstrong CM, D'Abronzo LS, Ning S, Evans CP, Gao AC. Activation of the ABCB1 Amplicon in Docetaxel- and Cabazitaxel-Resistant Prostate Cancer Cells. Mol Cancer Ther. 2021 Oct;20(10):2061-2070. doi:10.1158/1535-7163.MCT-20-0983. Epub 2021 Jul 29. PMID:34326198.
Katleba K, Lombard AP, Tsamouri MM, Baek HB, Nishida KS, Libertini SJ, Platero AJ, Ma AH, Pan CX, Ghosh PM, Mudryj M. Depletion of androgen receptor low molecular weight isoform reduces bladder tumor cell viability and induces apoptosis. Cancer Lett. 2021 Apr 28;504:49-57. doi:10.1016/j.canlet.2021.01.029. Epub 2021 Feb 4. PMID:33549708.
Armstrong CM, Liu C, Liu L, Yang JC, Lou W, Zhao R, Ning S, Lombard AP, Zhao J, D'Abronzo LS, Evans CP, Li PK, Gao AC. Steroid Sulfatase Stimulates Intracrine Androgen Synthesis and is a Therapeutic Target for Advanced Prostate Cancer. Clin Cancer Res. 2020 Nov 15;26(22):6064-6074. doi:10.1158/1078-0432.CCR-20-1682. Epub 2020 Sep 14. PMID:32928794.
Lombard AP, Gao AC. Resistance Mechanisms to Taxanes and PARP Inhibitors in Advanced Prostate Cancer. Curr Opin Endocr Metab Res. 2020 Feb;10:16-22. doi:10.1016/j.coemr.2020.02.006. Epub 2020 Feb 19. PMID:32258820.
Lombard AP, Liu C, Armstrong CM, D'Abronzo LS, Lou W, Evans CP, Gao AC. Wntless promotes cellular viability and resistance to enzalutamide in castration-resistant prostate cancer cells. Am J Clin Exp Urol. 2019 Aug 15;7(4):203-214. PMID:31511827.
Lombard AP, Liu C, Armstrong CM, D'Abronzo LS, Lou W, Chen H, Dall'Era M, Ghosh PM, Evans CP, Gao AC. Overexpressed ABCB1 Induces Olaparib-Taxane Cross-Resistance in Advanced Prostate Cancer. Transl Oncol. 2019 Jul;12(7):871-878. doi:10.1016/j.tranon.2019.04.007. Epub 2019 May 7. PMID:31075528.
Liu C, Lou W, Yang JC, Liu L, Armstrong CM, Lombard AP, Zhao R, Noel ODV, Tepper CG, Chen HW, Dall'Era M, Evans CP, Gao AC. Proteostasis by STUB1/HSP70 complex controls sensitivity to androgen receptor targeted therapy in advanced prostate cancer. Nat Commun. 2018 Nov 16;9(1):4700. doi:10.1038/s41467-018-07178-x. PMID:30446660.
Lombard AP, Liu L, Cucchiara V, Liu C, Armstrong CM, Zhao R, Yang JC, Lou W, Evans CP, Gao AC. Intra versus Inter Cross-resistance Determines Treatment Sequence between Taxane and AR-Targeting Therapies in Advanced Prostate Cancer. Mol Cancer Ther. 2018 Oct;17(10):2197-2205. doi:10.1158/1535-7163.MCT-17-1269. Epub 2018 Jun 11. PMID:29891490.